研究者
J-GLOBAL ID：201801013125319320
更新日: 2024年11月17日
齋藤 明子
サイトウ アキコ | Saito Akiko
所属機関・部署：
その他の所属（所属・部署名・職名） (1件)：
競争的資金等の研究課題 (1件)：
- 2010 - 2011 血液悪性腫瘍患者・医師間のコミュニケーションのあり方に関する研究
論文 (185件)：
-
Hiroaki Goto, Akiko Kada, Chitose Ogawa, Ritsuo Nishiuchi, Junko Yamanaka, Akihiro Iguchi, Masanori Nishi, Kimiyoshi Sakaguchi, Tadashi Kumamoto, Shinji Mochizuki, et al. Treatment of relapsed acute lymphoblastic leukemia in children: an observational study of the Japan Children’s Cancer Group. International Journal of Hematology. 2024. 120. 5. 631-638
-
Akira Honda, Yasutaka Masuda, Yu Oyama, Kensuke Matsuda, Hideaki Mizuno, Akiko M Saito, Yoshio Katayama, Norio Komatsu, Kazuhiro Toyama, Mineo Kurokawa. Prognostic factors of idiopathic hypereosinophilic syndrome: A nationwide survey in Japan. British journal of haematology. 2024
-
Hideo Saka, Masahide Oki, Yoshikane Yamauchi, Chiyoe Kitagawa, Akiko Kada, Akiko M Saito, Haruhiko Kondo, Hirotaka Kida, Noriaki Takahashi, Akihiro Bessho, et al. Talc slurry pleurodesis in patients with secondary intractable pneumothorax: A phase 2 study. Respiratory investigation. 2024. 62. 2. 277-283
-
Hideaki Ueki, Chitose Ogawa, Hiroaki Goto, Masanori Nishi, Junko Yamanaka, Shinji Mochizuki, Takuro Nishikawa, Tadashi Kumamoto, Ritsuo Nishiuchi, Atsushi Kikuta, et al. TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia. International journal of hematology. 2024
-
Tetsuya Mori, Tomoo Osumi, Akiko Kada, Kentaro Ohki, Yuhki Koga, Reiji Fukano, Naoto Fujita, Tetsuo Mitsui, Takeshi Mori, Akiko M Saito, et al. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial. European journal of haematology. 2023
もっと見る
MISC (65件)：
-
伊藤 典子, 二村 昌樹, 関水 匡大, 山本 松雄, 牧野 考代, 大塚 真理子, 齋藤 俊樹, 齋藤 明子, 永井 宏和. 臨床研究に関する教育コンテンツの一般無料公開の実施. 国立病院総合医学会講演抄録集. 2022. 76回. 1131-1131
-
森谷 邦彦, 今村 俊彦, 片山 紗乙莉, 戒能 明, 岡本 賢治, 横山 能文, 植村 優, 北澤 宏展, 関水 匡大, 平松 英文, et al. BFM基盤のプロトコールで治療をした日本人小児急性リンパ性白血病における症候性骨壊死の発症率は欧米人と同時である(Incidence of symptomatic ON in pediatric ALL treated with BFM based protocol is similar to children in western countries). 日本小児科学会雑誌. 2022. 126. 2. 294-294
-
Atsushi Sato, Hirohide Kawasaki, Takao Deguchi, Yoshiko Hashii, Yuka Iijima-Yamashita, Sachiko Yonezawa, Chiyo K. Imamura, Haruko Shima, Hirotoshi Sakaguchi, Yuichi Kodama, et al. Chemotherapy with the Use of TKIs Based on MRD Has the Potential to Avoid Hematopoietic Stem Cell Transplantation in Treatment for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL). Results of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study ALL-Ph13. BLOOD. 2021. 138
-
Hideki Nakayama, Chitose Ogawa, Masahiro Sekimizu, Hiroyuki Fujisaki, Yoshiyuki Kosaka, Hiroya Hashimoto, Akiko Saito, Keizo Horibe. Phase I Study of Inotuzumab Ozogamicin in Children with Relapsed/Refractory CD22-Positive Acute Lymphoblastic Leukemia in Japan (Ino-Ped-All-1). PEDIATRIC BLOOD & CANCER. 2021. 68
-
Genki Yamato, Hideki Muramatsu, Tomoyuki Watanabe, Takao Deguchi, Shotaro Iwamoto, Daisuke Hasegawa, Kiminori Terui, Takahiro Ueda, Tomoko Yokosuka, Shiro Tanaka, et al. Predictive Factors of Leukemia in Patients With Transient Abnormal Myelopoiesis: JCCG JPLSG TAM-10 Study. PEDIATRIC BLOOD & CANCER. 2019. 66. S36-S36
もっと見る
前のページに戻る
